Do anti-TNF-α drugs increase cancer risk in rheumatoid arthritis patients?

Inflammopharmacology

Volumn 21, Issue 2, 2013, Pages 125-127

  Clark, David A ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anti tumor necrosis factor ; Cancer; Meta analysis; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT;

CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENICITY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; HUMAN; LYMPHOMA; MELANOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SKIN CANCER; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; META ANALYSIS (TOPIC); NEOPLASM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; META-ANALYSIS AS TOPIC; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879500545     PISSN: 09254692     EISSN: 15685608     Source Type: Journal    
DOI: 10.1007/s10787-012-0158-0     Document Type: Review

References (14)

1. Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltslius N, Coster L, Geborek P, Jacobsen LT, Lindblad S, Rantapaa-Dahlqvist S, Saxne T, Klareskog L (2009) Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor α therapies. Does the risk change with the time since start of treatment? Arthr Rheum 60:3180-3189
2. Beacklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Irinel AI, Rosenquist R, Feltelius N, Sundstrom C, Klareskog L (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthr Rheum 54:692-701
3. Clark DA (2012) The end of evidence-based medicine? Inflammopharmacology 20:187-193
4. Drug Safety Committee (2012) Drug Safety Quarterly 4(2):1-4
5. Horton SC, Nam JL, Buch MH (2012) Safety of biologics in rheumatoid arthritis. Int J Clin Rheumatol 7:425-251 (Medscape CME, http://www.medscape. org/viewarticle/768769)
6. Kahneman D (2011) Thinking fast and slow. Doubleday, Canada
7. Lopez-Olivio MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, Fultom S, Suarez-Almazor ME (2012) Risk of malignancies in patients with rheumatoid arthritis treated with biological therapy. JAMA 308:898-908
8. Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P, Heresbacj D, Martin A, Schaeverbeke T, Salmon D, Lemann M, Hermine O, Raphael M, Ravaud P (2010) Lymphoma in patients treated with anti-TNF: results of the 3 year prospective French RATIO registry. Ann Rheum Dis 69:400-408
9. Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven A, Heatley R, Walsh C, Lawson R, Reynolds A, Emery P (2011) Malignancies associated with tumor necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70:1895-1904
10. Pallavicini FB, Caporali R, Sarzi-Puttini P, Atzeni F, Bazzanai C, Gorla R, Marchesoni A, Favalli EG, Montecucco C (2010) Tumor necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev 9:175-180
11. Schwartz RS (1974) Immunosuppressive chemotherapy and malignancy. Transpl Proc 6(Suppl 1):45-48
12. Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook G, Schneeweiss S (2006) Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthr Rheum 54:2757-2764
13. Solomon DH, Mercer E, Kavanaugh A (2012) Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis. Arthr Rheum 64:21-32
14. Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy. Arthr Rheum 56:2886-2895